All Access Articles |
- EyePoint Pharmaceuticals Receives Positive Recommendation for Duravyu™ Phase 3 Trials | 2025-11-19 | BIOTECHNOLOGY
- EyePoint Initiates Phase 3 Trial for Duravyu™ | 2025-10-15 | BIOTECHNOLOGY
- EyePoint Pharmaceuticals Enrolls 800 Patients for Wet AMD Treatment | 2025-07-29 | BIOTECHNOLOGY
- EyePoint Pharmaceuticals Boasts Strong Safety Profile and $370M Cash Position | 2025-03-04 | BIOTECHNOLOGY